Core Viewpoint - Stryker Corporation is receiving positive attention from analysts, with Jefferies reiterating a "Buy" rating based on its current valuation and recent orthopedic innovations [1][5] Group 1: Product Innovations - Stryker unveiled new advancements in orthopedic technology at the American Academy of Orthopedic Surgeons' 2026 Annual Meeting, including the Triathlon Gold knee implant and Medial Stabilized Insert, aimed at enhancing stability and addressing metal sensitivity issues [2][5] - The company expanded its Mako SmartRobotics platform and introduced new power tools such as the Mako Shoulder, RPS, and BPX and TPX HD tools, reinforcing its technology-driven approach in orthopedics [3][5] Group 2: Financial Performance - The current stock price of Stryker (SYK) is $381.89, reflecting a decrease of 0.70% or $2.70, with a trading range today between $380.87 and $384.51 [4] - Over the past year, Stryker's stock has reached a high of $404.87 and a low of $329.16, with a market capitalization of approximately $146.1 billion and a trading volume of 1,657,972 shares on the NYSE [4]